Busulfan was added at the dose of 4 mg/kg to 200 mg/kg cyclophosphamide in 81 patients (3-53 years, median 24) with aplastic anemia to reduce graft rejection. Graftversus-host disease (GVHD) prophylaxis comprised cyclosporine-methotrexate. The number of prior transfusions was 0-276 (median 26), and 48% had received prior immunosuppressive therapy. Two patients experienced primary graft failure, and 10 secondary rejection at 28-1001 days (median 317 days). The cumulative incidence of rejection was 22%; for heavily transfused patients (X50 U) it was 43% compared to 16% for the rest (P ¼ 0.06). Overall survival rate at 8 years was 56%; patients who received p15 and 415 transfusions was 78 and 50%, respectively (P ¼ 0.01), whereas it was 67 and 28% for p50 and 450 transfusions, respectively (P ¼ 0.002). In multivariate analysis, higher number of prior transfusions, shorter period of immunosuppression with cyclosporine and GVHD were associated with inferior survival; moreover, a higher risk of graft rejection were associated with a higher number of prior transfusions and a trend was observed for a shorter cyclosporine administration. Low-dose busulfan is feasible and may be helpful in patients exposed to o50 transfusions. However, rejection remains a significant problem, mainly in heavily transfused patients.
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Allogeneic hematopoietic stem cell transplantation (HSCT) is the definitive therapy for severe aplastic anemia (SAA), with survival rates ranging from 70 to 90%. [1] [2] [3] The major factors that limit the success of HSCT are graft rejection and graft-versus-host disease (GVHD). 1, 4, 5 Engraftment depends on the conditioning regimen, GVHD prophylaxis, number of donor marrow cells infused and alloimmunization of the patient. 1, 3, 4 The original conditioning regimen employed for patients with SAA was cyclosphosphamide alone, which was associated with graft rejection rates of 30-60% in patients who had received multiple prior transfusions. [6] [7] [8] It is now common to intensify pre-transplant immunosuppression with additional agents, such as antithymocyte globulin (ATG), total body irradiation (TBI), total lymphoid irradiation (TLI), or thoracoabdominal irradiation to reduce rejection rates. 1, [9] [10] [11] [12] [13] [14] Busulfan is an alkylating agent that is commonly used as part of the pre-transplant conditioning regimen for HSCT as a myeloablative agent, although it does possess limited immunosuppressive activity. 15, 16 Based on this, and in our previous unpublished data of about 50% rejection using only cyclosphosphamide in the conditioning regimen, we have added low-dose busulfan to standard cyclophosphamide in SAA patients in order to reduce graft rejection rates.
Patients and methods
From May 1993 to November 2001, 81 SAA patients underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings at three Brazilian Transplant Units, University of Sa˜o Paulo, State University of Campinas, and the Faculty of Medicine, Sa˜o Jose´do Rio Preto. All patients and donors provided informed consent according to the institutions' regulations.
The criteria for the diagnosis of SAA were patients with anemia requiring red blood cell support and/or with thrombocytopenia requiring platelet transfusions, along with one of the following: a hypoplastic marrow without blasts, neutrophil count of o0.5 Â 10 9 /l, and a platelet count of o20 Â 10 9 /l. Patient and donor characteristics are shown in Table 1 . Patients who had received more than 15 red cell and/or platelet units were considered 'polytransfused', and comprised 48 of the 74 patients (65%) in whom adequate information was available. Reliable transfusion data were not available in seven patients.
Conditioning regimen and GVHD prophylaxis
The preparative regimen was: busulfan 4 mg/kg in four divided doses of 1 mg/kg given orally every 6 h on day À6. There were no busulfan levels carried out; cyclophosphamide 50 mg/kg i.v. daily for 4 consecutive days on days À5 through À2. The graft was unmanipulated and GVHD prophylaxis comprised cyclosporine and short-course methotrexate (15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6, and þ 11). Cyclosporine was administered at the dose of 3 mg/kg/day i.v. in two divided doses from day À1, and was changed to 12.5 mg/kg/day p.o. per day in two divided doses as soon as possible. Two centers used the full dose of cyclosporine for 2 years and then tapered the drug gradually, whereas one used the full dose until day þ 50 and then tapered at the rate of 5% per month.
Acute and chronic GVHD were diagnosed and staged using standard criteria. Grade 2-4 acute GVHD was treated with i.v. methylprednisolone 2 mg/kg/day. Extensive chronic GVHD was treated with alternate-day cyclosporine and prednisone.
Engraftment
Neutrophil engraftment was defined as an absolute neutrophil count 40.5 Â 10 9 /l for 2 consecutive days, following a post-transplant nadir. Platelet engraftment was defined at the first of 7 consecutive days with a platelet count 420 Â 10 9 /l without platelet transfusion. Graft failure was defined as failure to reach an absolute granulocyte count of X0.5 Â 10 9 /l on day þ 28 for 2 consecutive days. Graft rejection was defined as a progressive decrease in blood counts after initial engraftment with marrow aplasia. Chimerism was determined using cytogenetics, VNTR analysis, or blood type when clinically indicated.
Supportive care
Patients were treated in single rooms equipped with HEPA filters. All blood products were irradiated but not leukocyte depleted. Broad-spectrum antibiotics and antifungal agents were administered whenever indicated.
Statistical analysis
Analysis was based on status of the patients on 1 November 2001. Overall survival (OS) was estimated using the Kaplan-Meier method. Cumulative incidence of graft failure and rejection was estimated using deaths unrelated to these causes as competing risks. The following factors were analyzed in a multivariate Cox's proportional-hazard regression models or logistic regression, when appropriate, for effect on graft failure, graft rejection, and OS: age, patient sex, donor sex, sex match, prior therapy, transfusion status, diagnosis-transplant interval, nucleated cell dose, cyclosporine withdrawal, acute GVHD, and chronic GVHD. The transfusion status was studied in two different ways: polytransfused (415 U) vs the rest and 'heavily transfused' (450 U; 4th quartile) vs the rest. S-Plus software version 2000 was used.
Results

Engraftment, graft failure, and rejection
The marrow cell doses infused had a median of 3.1 Â 10 8 /kg nucleated cells (range, 1.2-9.1). Two patients experienced primary graft failure and died of infection, one on day þ 36 without having had a second transplant and the other on day þ 84 after having undergone a second transplant from the same donor on day þ 77. Among the remaining patients, the median time to achieve an absolute neutrophil count X0.5 Â 10 9 /l was 20 days (range, , and the median time to achieve platelet transfusion independence was 25 days (range, 12-262).
Graft rejection after initial engraftment was seen in 10 patients. Secondary graft rejection occurred within 100 days in three patients, and beyond day 100 (after cyclosporine withdrawal) in seven. Among these 10 patients, three died before receiving the second transplant. Second transplant was performed in seven, four of whom are alive and well and three died due to infection before engraftment. The cumulative incidence of primary as well as secondary graft failure at 1 year was 22% (Figure 1a) .
The univariate analysis showed that graft failure plus rejection were only associated with transfusion status. The risk increased by a factor of 1.02 (95% CI: 1.00-1.04, P ¼ 0.04) for each transfused unit ( Table 2 ). The cumulative incidence of rejection for heavily transfused patients (X50 U) was 43% compared to 16% for the rest (P ¼ 0.06) (Figure 1b) .
Only the number of previous transfusions was statistically significant for rejection in the multivariate analysis (OR ¼ 1.02; 95% CI: 1.00-1.04; P ¼ 0.04). However, a trend was observed for longer cyclosporine administration to be favorable (OR ¼ 0.99; 95% CI: 0.99-1.00; P ¼ 0.06) ( Table 2 ).
Acute and chronic GVHD
Grade II-IV acute GVHD was seen in 37% of the evaluable patients. Clinical chronic GVHD developed in 24 of 61 (39%) evaluable patients, limited in six and extensive in 18. 
Causes of death
As shown in Table 3 , 26 out of 34 deaths were transplant related: bacterial infection (n ¼ 9), chronic GVHD (n ¼ 4), acute GVHD (n ¼ 3), central nervous system hemorrhage (n ¼ 3), fungal infections (n ¼ 2), CMV infection (n ¼ 1), veno-occlusive disease (n ¼ 1), multiorgan failure (n ¼ 1), pulmonary hemorrhage (n ¼ 1), and gastrointestinal hemorrhage (n ¼ 1). Eight deaths were due to rejection.
Survival
In all, 47 patients were alive at the last follow-up 55-2848 days (median 1757) after the transplant. The Kaplan-Meier estimate of survival was 56% at 6 years ( Figure 2a) . In univariate analysis, advanced age, previous treatment, higher number of transfusions, early cyclosporine withdrawal, and acute GVHD affected survival adversely ( Table 4 ). The 6-year survival for patients who received p15 and 415 transfusions was 78 and 50%, respectively (P ¼ 0.01) (Figure 2b ), whereas it was 67 and 28% for those who had received p50 and 450 transfusions, respectively (P ¼ 0.002) (Figure 2c ). Transfusion status, cyclosporine withdrawal, and acute GVHD were statistically significant for survival in multivariate analysis (Table 4) .
Discussion
Busulfan and cyclophosphamide, in combination, have been used as conditioning prior to allografting for many hematological disorders. However, busulfan has not been used in SAA, probably due to its low immunosuppressive activity. 17 The conditioning regimen in SAA has to immunosuppress the recipient adequately to enable marrow engraftment. While cyclophosphamide is well suited for this purpose, it is insufficient in some patients. Our use of lowdose busulfan was based on the evidence that it can enhance the immunosuppressive properties of cyclophosphamide. 18 Moreover, busulfan is cheaper than TBI and ATG in our setting. Our study demonstrates the feasibility of adding low-dose busulfan to cyclophosphamide to promote stable engraftment with acceptable toxicity and low cost. On the other hand, since rejection was still seen in ≥ 50U 43% Figure 1 Cumulative incidence of rejection* for all patients (a) and cumulative incidence of rejection* in patients heavily transfused X50 U (b) (*includes two patients with primary graft failure). 22% of patients, it is clear that the optimum dose of busulfan still remains to be defined. The rejection rate of 22% in a group of polytransfused patients compares favorably with 10% rejection rates in patients with low transfusion burden. 9, 19 A major factor associated with graft rejection has been sensitization to histocompatibility antigens through blood product transfusions. 9, [19] [20] [21] [22] The introduction of filtered, leukocyte-depleted red blood cell and platelet products, uncommon in Brazil until recently, should contribute to reducing pre-transplant alloimmunization now.
The number of transfusions was the most important factor affecting rejection and survival. One-quarter of patients had received at least 50 blood products. Their poor outcome explains in part the worse overall results of our patients compared to literature. Another important, controllable factor that contributed to poor outcome was early cyclosporine withdrawal. Based on our results, we have started using cyclosporine for an extended period of time rather than start tapering at 50 days with an aim to stop within 6 months.
This study suggests that the addition of busulfan to cyclophosphamide prior to allogeneic BMT in SAA is feasible. Low-dose busulfan may be a helpful addition in transplants for polytransfused patients with SAA exposed to less than 50 transfusions. However, graft rejection remains a significant problem, mainly in heavily transfused patients (X50 U). Further studies are required to clarify its exact contribution to reducing rejection and the optimum dose. 
